Dupixent severe asthma results should propel Sanofi, Regeneron drug to billions more in sales
admin 11th September 2017 Uncategorised 0Dupixent, the Sanofi and Regeneron drug already on a blockbuster arc in atopic dermatitis, has returned significant results in patients with severe asthma, another indication that is expected to add billions of dollars more in sales for the partners.
More: Dupixent severe asthma results should propel Sanofi, Regeneron drug to billions more in sales
Source: fierce